Unknown

The United States will target the EU, Switzerland, China, Japan and India, among others, in a Section 301 investigation, which will include scrutiny of the pharmaceutical sector. The focus will be on…

MFN deal number 17 offers a brand new gene therapy free of charge in the United States. Regeneron—the last of the 17 companies that received a letter from President Trump in July 2025 to reach an agre…

France’s Haute Autorité de Santé (HAS; National Health Authority) has taken the unusual step of writing an open letter to a business newspaper, Les Echos, “defending scientific independence in the fac…

Do the paintings of Edvard Munch offer a suitable depiction of where we stand with MFN? I made this suggestion at the start of a presentation I delivered in Oslo this week.   I was speaking at the ann…

The competitiveness of the European pharmaceutical sector in the face of immediate pressure from US policy and growing competition from China: that was the subject of an interview I gave to Dagens Med…

Not to be missed: truly thought-provoking comments on MFN from the Spanish Health Secretary, Javier Padilla in his Substack.   He starts with the question: “Could price transparency for medicines mean…